Astria Therapeutics, Inc.

. Entry Into a Material Definitive Agreement. On January 23, 2026 (the “ Closing Date ”), in connection with the Merger (as defined below) and immediately follo

of this Current Report on Form 8-K is incorporated into this Item 5.02 by reference. As a result of the Merger and pursuant to the terms of the Merger Agreement

by reference. Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. The information set forth in Item

by reference. In connection with the closing of the Merger, Astria (i) notified The Nasdaq Global Market (“ Nasdaq ”) that the Merger was consummated and (ii) r

by reference. At the Effective Time, each holder of Astria Common Stock immediately prior to the Effective Time (other than BioCryst, Astria or their wholly own

. Changes in Control of Registrant. The information set forth in Items 2.01, 3.03, 5.02 and 5.03 of this Current Report on Form 8-K is incorporated into this It

. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. The informa

by reference. Pursuant to the Merger Agreement, at the Effective Time, Astria’s certificate of incorporation was amended and restated in its entirety in the for

. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 2.1 Agreement and Plan of Merger by and among BioCryst Pharmaceuticals, Inc., Axel Me